Log in
LON:VEC

Vectura Group Share Forecast, Price & News

GBX 116.80
+2.00 (+1.74 %)
(As of 09/23/2020 12:00 AM ET)
Add
Compare
Today's Range
114.86
Now: GBX 116.80
118
50-Day Range
105.60
MA: GBX 111.51
118.40
52-Week Range
59.10
Now: GBX 116.80
121
Volume914,031 shs
Average Volume1.12 million shs
Market Capitalization£696.86 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD. Its generic partnering products include flutiform, VR315, VR506, VR730, VR632, VR2081, VR410, and Ellipta for the treatment of asthma; and Phase I clinical stage product is the VR475 (US) for the treatment of severe adult asthma. The company's Phase II clinical stage products comprise VR465 for treating respiratory syncytial virus infection; VR647 for the treatment of paediatric asthma; and VR736 for the treatment severe influenza. Its Phase III clinical stage products include QVM149 for the treatment of asthma; and VR475 (EU) for the treatment of severe adult asthma. The company also provides dry powder inhalers; pressurized meter dose inhalers; and smart nebulizers. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.
Read More
Vectura Group logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.4Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.00 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1249-667700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£178.30 million
Cash FlowGBX 12.43 per share
Book ValueGBX 69.20 per share

Profitability

Miscellaneous

Employees478
Market Cap£696.86 million
Next Earnings DateN/A
OptionableOptionable
GBX 116.80
+2.00 (+1.74 %)
(As of 09/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VEC News and Ratings via Email

Sign-up to receive the latest news and ratings for VEC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Vectura Group (LON:VEC) Frequently Asked Questions

How has Vectura Group's stock been impacted by COVID-19?

Vectura Group's stock was trading at GBX 81 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VEC stock has increased by 44.2% and is now trading at GBX 116.80.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Vectura Group?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vectura Group in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Vectura Group
.

What price target have analysts set for VEC?

4 Wall Street analysts have issued 1 year price targets for Vectura Group's shares. Their forecasts range from GBX 115 to GBX 134. On average, they anticipate Vectura Group's stock price to reach GBX 124.50 in the next twelve months. This suggests a possible upside of 6.6% from the stock's current price.
View analysts' price targets for Vectura Group
.

Who are some of Vectura Group's key competitors?

What other stocks do shareholders of Vectura Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vectura Group investors own include Hikma Pharmaceuticals (HIK), SkyePharma (SKP), BTG (BTG), iRobot (IRBT), SINR PHAR/PAR VTG FPD 0.01 (SPH), Sirius Minerals (SXX), Coats Group (COA), Griffin Mining (GFM), HSBC (HSBA) and Inmarsat (ISAT).

Who are Vectura Group's key executives?

Vectura Group's management team includes the following people:
  • Mr. James Ward-Lilley, CEO & Exec. Director (Age 54)
  • Mr. Paul Fry, CFO & Exec. Director
  • Mr. Anthony Fitzpatrick, Exec. VP of Operations
  • Elizabeth Knowles, Director of Investor Relations & Analysis
  • Mr. John Murphy, Gen. Counsel & Company Sec. (Age 66)

What is Vectura Group's stock symbol?

Vectura Group trades on the London Stock Exchange (LON) under the ticker symbol "VEC."

How do I buy shares of Vectura Group?

Shares of VEC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Vectura Group's stock price today?

One share of VEC stock can currently be purchased for approximately GBX 116.80.

How big of a company is Vectura Group?

Vectura Group has a market capitalization of £696.86 million and generates £178.30 million in revenue each year. Vectura Group employs 478 workers across the globe.

What is Vectura Group's official website?

The official website for Vectura Group is www.vectura.com.

How can I contact Vectura Group?

Vectura Group's mailing address is One Prospect West, CHIPPENHAM, SN14 6FH, United Kingdom. The company can be reached via phone at +44-1249-667700.

This page was last updated on 9/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.